# FS120 Phase 1/1b Study in Patients With Advanced Malignancies

> **NCT04648202** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **invoX Pharma Limited** · enrollment: 82 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** FS120

## Key facts

- **NCT ID:** NCT04648202
- **Lead sponsor:** invoX Pharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-18
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04648202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04648202, "FS120 Phase 1/1b Study in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04648202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*